Overview: Typhoid Antigen Rapid TestIntroduction: The Typhoid Antigen Rapid Test is a diagnostic tool designed to detect Salmonella typhi antigens in whole blood, serum, stool, or saliva samples, facilitating the screening of typhoid fever. Caused by Salmonella typhi, this systemic bacterial infection presents with fever, fatigue, and severe complications like intestinal perforation or death if untreated, particularly in endemic regions with poor sanitation. Per the 2023 World Health Organization guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a critical tool for rapid diagnosis during outbreaks. This rapid diagnostic falls under bacteriology and targets individuals with prolonged fever or travel history, addressing the challenge of early detection to guide antibiotic therapy with ciprofloxacin or ceftriaxone and prevent severe outcomes. With morbidity rates elevated due to waterborne transmission, the test supports public health efforts by enabling early case identification, facilitating water sanitation measures, and reducing mortality. Its multi-sample capability enhances its utility.Other Names: Typhoid Rapid Test.FDA Status: FDA approved, CLIA certified for bacteriology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by SD Bioline, this test advanced typhoid detection, providing a rapid alternative to blood culture.Purpose: The test screens for Salmonella typhi antigens to guide typhoid fever diagnosis, assess disease stage, and inform treatment and prevention strategies.Test Parameters: Presence of Salmonella typhi Antigen, detected with high specificity to indicate active infection, typically detectable in blood or stool within 1-2 weeks of symptom onset.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fever, fatigue, or recent travel to endemic areas.Specimen: Whole Blood 2-5 mL, Serum 2-5 mL, Stool 5-10 gm, Saliva 1-2 mL, collected using sterile EDTA/SST tubes or containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may denature antigens, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fever, fatigue, abdominal pain, or recent exposure to contaminated water/food, as well as any prior typhoid infections.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including death, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or antibiotic pre-treatment can affect results. Correlation with blood culture or PCR is recommended to confirm findings.Clinical Significance: A positive result indicates typhoid fever, necessitating antibiotic therapy and public health notification. A negative result may require follow-up testing if symptoms persist, especially if sampled too early.Specialist Consultation: Infectious disease specialists or tropical medicine experts should be consulted for case management, treatment planning, and coordination with public health authorities.Additional Supporting Tests: Blood culture, Typhoid PCR, or Widal test for confirmation.Test Limitations: The test may produce false negatives in early infection or false positives due to cross-reactivity, requiring a comprehensive diagnostic approach that includes microbiological confirmation.References: WHO Guidelines 2023, Journal of Infectious Diseases 2024, Tropical Medicine and International Health 2025.